Related Experiment Videos
Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response
Shannon L Maude1, Greg H Enders
1Department of Medicine, Gastroenterology Division, Department of Genetics, Abramson Cancer Center, University of Pennsylvania, 415 Curie Boulevard, Philadelphia, PA 19104, USA.
Cancer Research
|February 12, 2005
Summary
Cyclin-dependent kinases (Cdk) are crucial for cell proliferation and cancer. Inhibiting Cdk impairs the Chk1 pathway, triggering DNA damage responses and potentially enhancing cancer chemotherapy efficacy.
Area of Science:
- Cell Biology
- Molecular Oncology
- DNA Damage Response
Background:
- Cyclin-dependent kinases (Cdk) regulate cell proliferation and are implicated in human cancers.
- Cdk activity is essential for maintaining the integrity of the Chk1 pathway, a critical DNA damage response mechanism.
Purpose of the Study:
- To investigate the role of Cdk activity in maintaining Chk1 pathway function.
- To elucidate the downstream effects of Cdk inhibition on DNA damage signaling.
- To assess the potential of Cdk inhibition in cancer therapy.
Main Methods:
- Treatment of human cells (fibroblasts, U2OS) with small molecule Cdk inhibitors or dominant-negative Cdk2.
- Analysis of Chk1 expression, Chk1 activity, and Cdc25A levels.
- Assessment of DNA damage response markers including ATM, Chk2, and gammaH2AX foci.
- RNA interference for Chk1 and ectopic Chk1 expression.
- Combination treatment with Cdk/Chk1 inhibitors and etoposide.
Main Results:
- Cdk inhibition led to reduced Chk1 expression and activity, impairing its function.
- Cdk inhibition induced a DNA damage response, characterized by ATM/Chk2 activation and gammaH2AX foci.
- Chk1 down-regulation was necessary for the full DNA damage response phenotype induced by Cdk inhibitors.
- Combined inhibition of Cdk and Chk1 enhanced the cytotoxicity of etoposide.
Conclusions:
- Cdk activity is required for proper Chk1 pathway function.
- Cdk inhibition triggers a DNA damage response by down-regulating Chk1.
- Targeting Cdk may represent a viable strategy to enhance the efficacy of DNA-damaging cancer chemotherapies.